NEW YORK, NY / ACCESSWIRE / May 4, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.
BLU Shareholders Click Here: https://www.zlk.com/pslra-1/bellus-health-inc-loss-submission-form?prid=15452&wire=1
NEPT Shareholders Click Here: https://www.zlk.com/pslra-1/neptune-wellness-solutions-inc-loss-submission-form?prid=15452&wire=1
ACAD Shareholders Click Here: https://www.zlk.com/pslra-1/acadia-pharmaceuticals-inc-loss-submission-form?prid=15452&wire=1
* ADDITIONAL INFORMATION BELOW *
BELLUS Health Inc. (NASDAQ:BLU)
BLU Lawsuit on behalf of: investors who purchased September 5, 2019 - July 5, 2020
Lead Plaintiff Deadline : May 17, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/bellus-health-inc-loss-submission-form?prid=15452&wire=1
According to the filed complaint, during the class period, BELLUS Health Inc. made materially false and/or misleading statements and/or failed to disclose that: while BLU-5937's "high selectivity" contributed to the drug causing little to no taste alteration in chronic cough patients, that high selectivity also contributed to the drug potentially being less efficacious and thus likely not be able to meet the primary endpoint of the Company's Phase 2 trial.
Neptune Wellness Solutions Inc. (NASDAQ:NEPT)
NEPT Lawsuit on behalf of: investors who purchased July 24, 2019 - February 16, 2021
Lead Plaintiff Deadline : May 17, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/neptune-wellness-solutions-inc-loss-submission-form?prid=15452&wire=1
According to the filed complaint, during the class period, Neptune Wellness Solutions Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the cost of Neptune's integration of the assets and operations acquired in the SugarLeaf Acquisition would be larger than the Company had acknowledged, placing significant strain on the Company's capital reserves; (ii) accordingly, it was reasonably foreseeable that the company would need to conduct additional stock offerings to raise more capital; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD)
ACAD Lawsuit on behalf of: investors who purchased June 15, 2020 - April 4, 2021
Lead Plaintiff Deadline : June 18, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/acadia-pharmaceuticals-inc-loss-submission-form?prid=15452&wire=1
According to the filed complaint, during the class period, Acadia Pharmaceuticals Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the materials submitted in support of the pimavanserin sNDA contained statistical and design deficiencies; (ii) accordingly, the pimavanserin sNDA lacked the evidentiary support that the Company had led investors to believe it possessed; (iii) the FDA was unlikely to approve the pimavanserin sNDA in its present form; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
SOURCE: Levi & Korsinsky, LLP